TRLV — Trulieve Cannabis Corp. Subordi

Is TRLV overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Oversold As of October 3, 2026

Trulieve Cannabis Corp. Subordi (TRLV) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $10.72. The rating moved from Overbought to Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Trulieve Cannabis Corp. Subordi exhibits the benefits of scale and an established multi‑state retail and supply footprint, which supports steady cash generation relative to smaller operators. Near‑term upside depends on continued execution on margin expansion, prudent balance‑sheet management and any favorable state or federal regulatory developments; however, sectorwide macro sensitivity, federal prohibition risks, and local competitive pressures create meaningful volatility. Liquidity management, successful cost control, and progress on higher‑margin categories will determine whether the company can convert operational scale into durable margin improvement under current market uncertainty.

Key factors

  • Large retail footprint and recognized consumer brand in multiple U.S. adult‑use and medical markets, supporting stable revenue base
  • Demonstrated operational scale that can drive cost efficiencies (distribution, cultivation, manufacturing) versus smaller competitors
  • Potential near‑term catalysts from state-level adult‑use expansions, store openings, product mix improvements and targeted M&A
  • Improved capital access and balance‑sheet management relative to early‑cycle peers could reduce refinancing stress if liquidity preserved
  • Sectorwide sentiment driven by macro risk‑off and capital markets weakness, which can mute upside despite company‑level progress
  • Regulatory momentum (federal banking reform / federal descheduling) remains a binary upside catalyst but is uncertain in timing

Risks

  • Federal prohibition and adverse tax treatment (e.g., 280E) that limit profitability and create complex compliance burdens
  • Banking, payments and capital‑markets access constraints that can increase funding costs or restrict growth initiatives
  • Intense state‑level competition and local oversupply that pressure retail pricing and margins
  • Execution risk on new market entries and integration of any acquisitions, including cost overruns or slower synergies
  • Commodity‑like pricing for flower and product commoditization reducing gross margins over time
  • Regulatory shifts at the state level (licensing changes, tax increases) that can reduce revenue or increase operating costs
  • High leverage or unfavorable subordinated capital structure could amplify downside in a stressed macro scenario
  • Sensitivity to macro risk‑off flows and episodic volume declines during weak consumer sentiment

See today's live rating, score and targets

Members see the live hourly rating for TRLV — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.